Wikipedia

Jacob Hooker

Jacob M. Hooker is an American chemist and expert in molecular imaging, particularly in the development and application of simultaneous MRI and PET. He has contributed major advances on the entire spectrum of research from fundamental chemistry methodology with radioisotopes to human neuroimaging.[citation needed]

Life and education edit

Hooker grew up just outside of Asheville, North Carolina and attended Enka High School. He graduated from North Carolina State University in 2002 with bachelor of science degrees in Textile Chemistry and Chemistry. He then earned his doctorate of philosophy in Chemistry at the University of California, Berkeley, mentored by Professor Matt Francis. After hearing a neuroimaging presentation in 2006 by National Medal of Science recipient Joanna Fowler, Hooker immersed himself in postdoctoral training under her mentorship at the Brookhaven National Laboratory. Fowler recalls having Jacob as a postdoc "getting him was like winning the lottery" "He's going to ask questions we haven't thought of before."[1] Hooker conducted his postdoctoral training with Fowler as a Goldhaber Distinguished Fellow, developing new neuroscience-oriented imaging methods and protocols.

Research and achievements edit

Hooker relocated to Charlestown, MA in 2009 at the initiation of his independent research career at the Martinos Center. He co-designed and scratch-built a cyclotron and radiopharmacy facility housing a Siemens Eclipse HP Cyclotron, completed early 2011. The production and imaging facility – part of the Martinos Center Research Core – provides imaging tools for all stages of translational research.

The mission of his academic research lab is "to accelerate the study of the living, human brain and nervous system through development and application of molecular imaging agents." An organic chemist by training, Hooker and his research group are devoted to enhance understanding of the healthy brain and dysfunction in diseases including Alzheimer's, Autism and Schizophrenia.[citation needed]

His research focus centers on the themes of neuroepigenetics, radiochemistry methods development and neuroimaging methods development; highlights are provided in the following section.

Major publication themes edit

Hooker has published over 100 papers[2] most notably in the domains of:

 
MR-PET: [11C]Martinostat uptake in living human brain.

Neuroepigenetics: visualizing histone deacetylase enzymes with PET edit

Work from Hooker's group published in August 2016 – Wey & Gilbert et al 2016 Science Translational Medicine revealed the first visual maps of neuroepigenetic function in the living human brain using the Class-I histone deacetylase (HDAC) PET imaging probe [11C]Martinostat.[3] This work demonstrated a link between quantitative HDAC maps of the brain and the expression of plasticity and disease-related genes under HDAC control. The human imaging report was built on a background of tool development in the Hooker lab spanning seven years, wherein small molecule histone deacetylase (HDAC) inhibitors were systematically screened and refined to resolve chemical leads with Class-I HDAC isoform selectivity, outstanding brain penetrance and appropriate binding kinetics.[improper synthesis?][4][5][6][7][8][9][10][11][12][13][14][15] The first-in-human imaging paper set the stage for Hooker's ongoing work to measure and map HDAC density, distribution and connectivity in diverse diseases, in vivo.

Radiochemistry methods development: changing the chemical landscape for PET tracer production edit

Hooker and his colleagues have made remarkable advances innovating in chemical and radiochemical synthetic methods to increase efficiency and expand capabilities of PET imaging. The most common radioisotopes for medical imaging agents, carbon-11 and fluorine-18, have a half-lives of 20.4 and 109.8 minutes, respectively. This presents significant demands in streamlining chemical synthesis steps and maximizing reaction yields in order to resolve sufficient quantities of radiotracer to complete required quality control steps before a dose can be 'released' for injection into a human subject. A critical element to this innovation has been the collaborative research environment cultivated within Hooker's lab to rethink dogmatic approaches to chemical endpoints or adapt cutting-edge organometallic chemistry to meet the needs of radiotracer synthesis.

Research Highlights in Radiochemistry

  • In a 2011 Science paper, in collaboration with Tobias Ritter's lab at Harvard, Hooker demonstrated for the first time that a palladium-IV complex could fundamentally 'switch' the way fluoride behaves in chemical reactions, most aptly described as a switch from a nucleophile to an electrophile.[16] In a separate and subsequent advance, this unconventional mindset led to the first demonstration of a concerted nucleophilic aromatic substitution reaction, published in Nature in 2016.[17]
  • Hooker and Stephen Buchwald (MIT) developed a strategy for labeling molecules with carbon-11 using cyanide nearly instantaneously using a biaryl phosphine Pd(0) complexes.[18]
  • Hooker and John T. Groves (Princeton) demonstrated the first example of radiofluorination with fluoride-18 using C-H [19] and decarboxylation with manganese catalysts.[20]

Neuroimaging methods development: functional MR and PET brain imaging edit

A new application for radiolabeled glucose: The main energy source of the brain, glucose, provides a significant biological foothold to image brain activity via energy use through cellular uptake and trapping of the glucose analog, [18F]fludexyglucose (FDG). Since the mid-1970s, FDG has been applied as a 'bolus' at the beginning of an imaging experiment with regional uptake measured and mapped after a waiting period during which brain cells unknowingly substitute radiolabeled FDG for normal glucose. Like long-exposure photographs, bolus FDG PET imaging paradigms are robust and valuable in identifying otherwise-inaccessible tissue types with differential metabolism (e.g. cancerous tumors, post-ischemic myocardial lesions, hypometabolic brain regions following aneurysm), but lack kinetic detail.

Despite some 40 years of [18F]FDG access and research, the dynamics of glucose utilization in response to brain activation remain poorly understood. Through innovations in radiotracer delivery and PET image processing, Prof. Hooker and his team were able to develop a method for brain glucose monitoring that produced something more like a movie, reporting changes in glucose use in response to multiple stimuli during a single PET scan.[21] The lab is now expanding the concept of dynamic, functional PET imaging to measure real-time neurotransmitter release in the living human brain.

Evidence of glial activation in the brain with chronic low back pain: In a similar reconfiguration of existing tools, Hooker and his faculty colleague and fMRI expert, Marco Loggia were the first to use the novel technology of integrated positron emission tomography-magnetic resonance imaging with the radioligand [11C]-PBR28 to demonstrate increased brain levels of the translocator protein (TSPO), a marker of glial activation, in patients with chronic low back pain.[22] The work not only provided a new biological mechanism to explore in chronic pain treatment, it also helped to spark a major programmatic theme at MGH in neuroinflammation; borne from this was the Boston-wide Neuroinflammation Think Tank which bridges together major stakeholders from academia, medicine, and the pharmaceutical industry.

Awards and honors edit

In 2016, Hooker was named as a Phyllis and Jerome Lyle Rappaport MGH Research Scholar which acknowledges 'forward thinking researchers with the funding they need to take their work into uncharted territories'. His research proposal, entitled Visualizing Chemical Dysfunction in the Human Brain was awarded $500,000 over five years for its tangible vision to develop novel imaging tools and accelerate their application in in vivo imaging to understand normal brain growth, aging and function and draw comparisons to brain diseases such as schizophrenia, Alzheimer's disease, dementia and Autism.

In 2015, the Brain & Behavior Research Foundation acknowledged Jacob with an Independent Investigator Award for research piloting neuroimaging in patients with Schizophrenia. He was named by The Scientist magazine as a Scientist to Watch, and in an article dubbing him 'The Mind Mapper' was among inaugural winners of the Talented 12 Award from the American Chemical Society's C & E News.[23]

Hooker was named by the National Academy of Sciences as a prestigious Kavli Fellow for a five-year tenure (2012-2017) and as a Keck Futures Initiative Fellow (2013-2015).[citation needed]

In 2009 he became a Department of Energy recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE) for pioneering research on adapting modern synthetic chemistry to the development of new tools for tracking and quantifying biochemical transformations and the movement of complex molecules in living systems, as well as outreach and mentorship to visiting students and scholars.[24]

References edit

  1. ^ Grant, Bob. "Jacob Hooker: Weaver of Brain Science". The Scientist. Retrieved 25 April 2016.
  2. ^ Search Results for author Hooker JM on PubMed.
  3. ^ Wey, Hsiao-Ying; Gilbert, Tonya M.; Zürcher, Nicole R.; She, Angela; Bhanot, Anisha; Taillon, Brendan D.; Schroeder, Fredrick A.; Wang, Changing; Haggarty, Stephen J.; Hooker, Jacob M. (2016). "Insights into neuroepigenetics through human histone deacetylase PET imaging". Science Translational Medicine. 8 (351): 351ra106. doi:10.1126/scitranslmed.aaf7551. PMC 5784409. PMID 27510902.[non-primary source needed]
  4. ^ Hooker, Jacob M.; Kim, Sung Won; Alexoff, David; Xu, Youwen; Shea, Colleen; Reid, Alicia; Volkow, Nora; Fowler, Joanna S. (2010). "Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography". ACS Chemical Neuroscience. 1 (1): 65–73. doi:10.1021/cn9000268. PMC 2908422. PMID 20657706.[non-primary source needed]
  5. ^ Wang, Changning; Eessalu, Thomas E.; Barth, Vanessa N.; Mitch, Charles H.; Wagner, Florence F.; Hong, Yijia; Neelamegam, Ramesh; Schroeder, Frederick A.; Holson, Edward B. (2013). "Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain". American Journal of Nuclear Medicine and Molecular Imaging. 4 (1): 29–38. PMC 3867727. PMID 24380043.
  6. ^ Seo, Young Jun; Muench, Lisa; Reid, Alicia; Chen, Jinzhu; Kang, Yeona; Hooker, Jacob M.; Volkow, Nora D.; Fowler, Joanna S.; Kim, Sung Won (2013). "Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain". Bioorganic & Medicinal Chemistry Letters. 23 (24): 6700–6705. doi:10.1016/j.bmcl.2013.10.038. PMC 4007514. PMID 24210501.[non-primary source needed]
  7. ^ Kim, Sung Won; Hooker, Jacob M.; Otto, Nicola; Win, Khaing; Muench, Lisa; Shea, Colleen; Carter, Pauline; King, Payton; Reid, Alicia E.; Volkow, Nora D.; Fowler, Joanna S. (2013). "Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET". Nuclear Medicine and Biology. 40 (7): 912–918. doi:10.1016/j.nucmedbio.2013.06.007. PMC 3769509. PMID 23906667.[non-primary source needed]
  8. ^ Schroeder, Frederick A.; Chonde, Daniel B.; Riley, Misha M.; Moseley, Christian K.; Granda, Michael L.; Wilson, Colin M.; Wagner, Florence F.; Zhang, Yan-Ling; Gale, Jennifer; Holson, Edward B.; Haggarty, Stephen J.; Hooker, Jacob M. (2013). "FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors". Neuroscience Letters. 550: 119–124. doi:10.1016/j.neulet.2013.06.016. PMC 3750730. PMID 23810801.[non-primary source needed]
  9. ^ Wang, Yajie; Zhang, Yan-Ling; Hennig, Krista; Gale, Jennifer P.; Hong, Yijia; Cha, Anna; Riley, Misha; Wagner, Florence; Haggarty, Stephen J.; Holson, Edward; Hooker, Jacob (2013). "Class I HDAC imaging using [3H]CI-994 autoradiography". Epigenetics. 8 (7): 756–764. doi:10.4161/epi.25202. PMC 3781195. PMID 23803584.[non-primary source needed]
  10. ^ Schroeder, Frederick A.; Lewis, Michael C.; Fass, Daniel M.; Wagner, Florence F.; Zhang, Yan-Ling; Hennig, Krista M.; Gale, Jennifer; Zhao, Wen-Ning; Reis, Surya; Barker, Douglas D.; Berry-Scott, Erin; Kim, Sung Won; Clore, Elizabeth L.; Hooker, Jacob M.; Holson, Edward B.; Haggarty, Stephen J.; Petryshen, Tracey L. (2013). "A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests". PLOS ONE. 8 (8): e71323. Bibcode:2013PLoSO...871323S. doi:10.1371/journal.pone.0071323. PMC 3743770. PMID 23967191.[non-primary source needed]
  11. ^ Seo, Young Jun; Kang, Yeona; Muench, Lisa; Reid, Alicia; Caesar, Shannon; Jean, Logan; Wagner, Florence; Holson, Edward; Haggarty, Stephen J.; Weiss, Philipp; King, Payton; Carter, Pauline; Volkow, Nora D.; Fowler, Joanna S.; Hooker, Jacob M.; Kim, Sung Won (2014). "Image-Guided Synthesis Reveals Potent Blood-Brain Barrier Permeable Histone Deacetylase Inhibitors". ACS Chemical Neuroscience. 5 (7): 588–596. doi:10.1021/cn500021p. PMC 4102966. PMID 24780082.[non-primary source needed]
  12. ^ Wang, Changning; Schroeder, Frederick A.; Wey, Hsiao-Ying; Borra, Ronald; Wagner, Florence F.; Reis, Surya; Kim, Sung Won; Holson, Edward B.; Haggarty, Stephen J.; Hooker, Jacob M. (2014). "In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs". Journal of Medicinal Chemistry. 57 (19): 7999–8009. doi:10.1021/jm500872p. PMC 4191584. PMID 25203558.[non-primary source needed]
  13. ^ Schroeder, F. A.; Wang, C.; Van De Bittner, G. C.; Neelamegam, R.; Takakura, W. R.; Karunakaran, A.; Wey, H. Y.; Reis, S. A.; Gale, J.; Zhang, Y. L.; Holson, E. B.; Haggarty, S. J.; Hooker, J. M. (2014). "PET Imaging Demonstrates Histone Deacetylase Target Engagement and Clarifies Brain Penetrance of Known and Novel Small Molecule Inhibitors in Rat". ACS Chemical Neuroscience. 5 (10): 1055–1062. doi:10.1021/cn500162j. PMC 4198064. PMID 25188794.[non-primary source needed]
  14. ^ Wey, Hsiao-Ying; Wang, Changning; Schroeder, Frederick A.; Logan, Jean; Price, Julie C.; Hooker, Jacob M. (2015). "Kinetic Analysis and Quantification of [11C]Martinostat for in Vivo HDAC Imaging of the Brain". ACS Chemical Neuroscience. 6 (5): 708–715. doi:10.1021/acschemneuro.5b00066. PMC 4439341. PMID 25768025.[non-primary source needed]
  15. ^ Strebl, Martin G.; Wang, Changning; Schroeder, Frederick A.; Placzek, Michael S.; Wey, Hsiao-Ying; Van De Bittner, Genevieve C.; Neelamegam, Ramesh; Hooker, Jacob M. (2016). "Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance". ACS Chemical Neuroscience. 7 (5): 528–533. doi:10.1021/acschemneuro.5b00297. PMC 5784429. PMID 26675505.[non-primary source needed]
  16. ^ Lee, Eunsung; Kamlet, Adam S.; Powers, David C.; Neumann, Constanze N.; Boursalian, Gregory B.; Furuya, Takeru; Choi, Daniel C.; Hooker, Jacob M.; Ritter, Tobias (2011). "A Fluoride-Derived Electrophilic Late-Stage Fluorination Reagent for PET Imaging". Science. 334 (6056): 639–642. Bibcode:2011Sci...334..639L. doi:10.1126/science.1212625. PMC 3229297. PMID 22053044.[non-primary source needed]
  17. ^ Neumann, Constanze N.; Hooker, Jacob M.; Ritter, Tobias (2016). "Concerted nucleophilic aromatic substitution with 19F− and 18F−". Nature. 534 (7607): 369–373. Bibcode:2016Natur.534..369N. doi:10.1038/nature17667. PMC 4911285. PMID 27281221.[non-primary source needed]
  18. ^ Lee, Hong Geun; Milner, Phillip J.; Placzek, Michael S.; Buchwald, Stephen L.; Hooker, Jacob M. (2015). "Virtually Instantaneous, Room-Temperature [11C]-Cyanation Using Biaryl Phosphine Pd(0) Complexes". Journal of the American Chemical Society. 137 (2): 648–651. doi:10.1021/ja512115s. PMC 4394387. PMID 25565277.[non-primary source needed]
  19. ^ Huang, Xiongyi; Liu, Wei; Ren, Hong; Neelamegam, Ramesh; Hooker, Jacob M.; Groves, John T. (2014). "Late Stage Benzylic C–H Fluorination with [18F]Fluoride for PET Imaging". Journal of the American Chemical Society. 136 (19): 6842–6845. doi:10.1021/ja5039819. PMID 24766544.[non-primary source needed]
  20. ^ Huang, Xiongyi; Liu, Wei; Hooker, Jacob M.; Groves, John T. (2015). "Targeted Fluorination with the Fluoride Ion by Manganese-Catalyzed Decarboxylation". Angewandte Chemie International Edition. 54 (17): 5241–5245. doi:10.1002/anie.201500399. PMID 25736895.[non-primary source needed]
  21. ^ Villien, Marjorie; Wey, Hsiao-Ying; Mandeville, Joseph B.; Catana, Ciprian; Polimeni, Jonathan R.; Sander, Christin Y.; Zürcher, Nicole R.; Chonde, Daniel B.; Fowler, Joanna S.; Rosen, Bruce R.; Hooker, Jacob M. (2014). "Dynamic functional imaging of brain glucose utilization using fPET-FDG". NeuroImage. 100: 192–199. doi:10.1016/j.neuroimage.2014.06.025. PMC 4224310. PMID 24936683.[non-primary source needed]
  22. ^ Loggia, Marco L.; Chonde, Daniel B.; Akeju, Oluwaseun; Arabasz, Grae; Catana, Ciprian; Edwards, Robert R.; Hill, Elena; Hsu, Shirley; Izquierdo-Garcia, David; Ji, Ru-Rong; Riley, Misha; Wasan, Ajay D.; Zürcher, Nicole R.; Albrecht, Daniel S.; Vangel, Mark G.; Rosen, Bruce R.; Napadow, Vitaly; Hooker, Jacob M. (2015). "Evidence for brain glial activation in chronic pain patients". Brain. 138 (3): 604–615. doi:10.1093/brain/awu377. PMC 4339770. PMID 25582579.[non-primary source needed]
  23. ^ Halford, Bethany (2015). "Jacob Hooker: The Mind Mapper". Chemical & Engineering News. 93 (27): 15. doi:10.1021/cen-09327-cover5.
  24. ^ "DOE's Winners Since 1996 | U.S. DOE Office of Science (SC)". science.osti.gov. 2019-08-13. Retrieved 2024-02-29.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Jacob_Hooker&oldid=1218411488"